Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Overview of attention for article published in Arthritis Research & Therapy, September 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

patent: 1 patent

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 24 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

NOVEL USE OF MELANOCORTIN-1 RECEPTOR AGONIST

Application WO-2023145959-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.